Drug insight: novel small molecules and drugs for immunosuppression.
Gastrointestinal diseases can result from the inadequate or excessive response of the immune system to self or innocuous antigens. Moreover, the physiologic activation of the immune system against non-self antigens is a major clinical problem in liver organ transplantation. At present, many drugs are available that suppress the activation of the immune system, although most of the currently used immunosuppressive drugs lack specificity in terms of their molecular targets and, therefore, have the potential to generate numerous side effects. The advances that have been made in understanding the molecular events that underlie the activation of the immune system have led to the development of a new generation of 'small molecules' that are endowed with immunosuppressive properties and can serve as immunomodulatory agents. Among these new small molecules, inhibitors of Janus kinase 3, p21-Rac1 and p38 mitogen-activated protein kinase represent the most innovative approach to immunosuppression, and could be a promising alternative to current immunosuppressive therapies. Here, we report on the progress that has been made in the development of small molecules in the field of gastroenterology.
Fantini
Massimo C
MC
University of Rome Tor Vergata, Italy.
Becker
Christoph
C
Kiesslich
Ralf
R
Neurath
Markus F
MF
D000818:Animals; D005762:Gastroenterology / Q000639:trends; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007107:Immune System / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000737:chemistry* / Q000627:therapeutic use*; D008970:Molecular Weight
D007166:Immunosuppressive Agents